Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.38 |
| ▸ | HMGCR | P04035 | 2/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10927069 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL7527151 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL1279585 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL7527108 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL9052855 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL23647759 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL18037106 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL11086709 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL887761 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 | |
| SCHEMBL887750 | 1.00 | TSHR (0.44) | TSHRTHRBFAAHTRPV1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-11901249-B2 | Curable composition and cured product thereof | DIC CORPORATION (JP) | 2024-02-13 | — | — | US | disclosed |
| US-11873356-B2 | Curable composition and cured product thereof | DIC CORPORATION (JP) | 2024-01-16 | — | — | US | disclosed |
| US-11548977-B2 | Active ester resin and composition and cured product using the same | DIC CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| US-11407708-B2 | Active ester compound and composition and cured product obtained using the same | DIC CORPORATION (JP) | 2022-08-09 | — | — | US | disclosed |
| US-20210032383-A1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | DIC CORPORATION (JP) | 2021-02-04 | — | — | US | disclosed |
| US-20210009804-A1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | DIC CORPORATION (JP) | 2021-01-14 | — | — | US | disclosed |
| US-20200216603-A1 | ACTIVE ESTER RESIN AND COMPOSITION AND CURED PRODUCT USING THE SAME | DIC CORPORATION (JP) | 2020-07-09 | — | — | US | disclosed |
| US-20200207700-A1 | ACTIVE ESTER COMPOUND AND COMPOSITION AND CURED PRODUCT OBTAINED USING THE SAME | DIC CORPORATION (JP) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207700-A1 | ACTIVE ESTER COMPOUND AND COMPOSITION AND CURED PRODUCT OBTAINED USING THE SAME | CRAT, CYP19A1, EP300 | TSHR 4741/4885THRB 3159/4885FAAH 501/4885 |
| US-11407708-B2 | Active ester compound and composition and cured product obtained using the same | CRAT, CYP19A1, EP300 | TSHR 4741/4885THRB 3159/4885FAAH 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.